Charles River Laboratories ROE 2010-2024 | CRL

Current and historical return on equity (ROE) values for Charles River Laboratories (CRL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Charles River Laboratories ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-06-30 $0.44B $3.73B 12.35%
2024-03-31 $0.44B $3.65B 12.85%
2023-12-31 $0.47B $3.60B 14.27%
2023-09-30 $0.47B $3.31B 14.97%
2023-06-30 $0.48B $3.26B 16.12%
2023-03-31 $0.50B $3.11B 17.40%
2022-12-31 $0.49B $2.98B 17.83%
2022-09-30 $0.44B $2.63B 16.70%
2022-06-30 $0.44B $2.65B 17.31%
2022-03-31 $0.42B $2.62B 17.04%
2021-12-31 $0.39B $2.54B 16.49%
2021-09-30 $0.40B $2.43B 17.48%
2021-06-30 $0.40B $2.32B 18.57%
2021-03-31 $0.38B $2.19B 18.83%
2020-12-31 $0.36B $2.12B 19.59%
2020-09-30 $0.30B $1.90B 17.32%
2020-06-30 $0.27B $1.76B 16.46%
2020-03-31 $0.25B $1.66B 15.78%
2019-12-31 $0.25B $1.64B 16.71%
2019-09-30 $0.23B $1.54B 16.24%
2019-06-30 $0.22B $1.46B 16.11%
2019-03-31 $0.23B $1.40B 17.74%
2018-12-31 $0.23B $1.32B 18.51%
2018-09-30 $0.14B $1.26B 11.83%
2018-06-30 $0.13B $1.19B 11.73%
2018-03-31 $0.13B $1.14B 12.34%
2017-12-31 $0.12B $1.05B 12.56%
2017-09-30 $0.20B $1.03B 21.35%
2017-06-30 $0.18B $0.97B 20.69%
2017-03-31 $0.17B $0.88B 19.26%
2016-12-31 $0.16B $0.84B 18.61%
2016-09-30 $0.14B $0.87B 17.58%
2016-06-30 $0.14B $0.84B 18.39%
2016-03-31 $0.16B $0.78B 21.11%
2015-12-31 $0.15B $0.74B 21.27%
2015-09-30 $0.15B $0.71B 21.02%
2015-06-30 $0.14B $0.71B 20.56%
2015-03-31 $0.13B $0.67B 18.72%
2014-12-31 $0.13B $0.68B 18.50%
2014-09-30 $0.12B $0.67B 17.53%
2014-06-30 $0.12B $0.68B 17.48%
2014-03-31 $0.11B $0.70B 16.43%
2013-12-31 $0.10B $0.64B 15.94%
2013-09-30 $0.10B $0.66B 16.04%
2013-06-30 $0.09B $0.65B 14.97%
2013-03-31 $0.10B $0.63B 16.01%
2012-12-31 $0.10B $0.60B 16.53%
2012-09-30 $0.11B $0.60B 18.69%
2012-06-30 $0.10B $0.57B 18.65%
2012-03-31 $0.10B $0.56B 18.79%
2011-12-31 $0.11B $0.53B 19.61%
2011-09-30 $-0.26B $0.54B -43.94%
2011-06-30 $-0.31B $0.59B -42.47%
2011-03-31 $-0.32B $0.56B -35.17%
2010-12-31 $-0.34B $0.69B -30.01%
2010-09-30 $0.02B $1.04B 1.85%
2010-06-30 $0.09B $1.39B 6.25%
2010-03-31 $0.11B $1.38B 7.87%
2009-12-31 $0.11B $1.37B 8.73%
Sector Industry Market Cap Revenue
Medical Medical Services $9.742B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
Viatris (VTRS) United States $13.858B 4.22
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00